 NEW YORK, Aug. 19, 2020 GLOBE NEWSWIRE -- Bragar Eagel Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Velocity Financial, Inc. NYSE: VEL, FirstEnergy Corp. NYSE: FE, MEI Pharma, Inc. NADAQ: MEIP, and Cabot Oil Gas Corporation NYSE: COG. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Velocity Financial, Inc. NYSE: VELClass Period: Common stock purchased pursuant andor traceable to the Registration Statement and Prospectus, as amended, issued in connection with Velocitys January 2020 IPO.Lead Plaintiff Deadline: September 28, 2020Velocity is a real estate finance company that originates and manages loans issued to borrowers nationwide to finance the purchase of small residential rental and commercial real estate investment properties.On April 8, 2020, Velocity announced its financial and operational results for the 2019 fourth quarter and full year. The Company stated it had suspended all loan origination operations due to market volatility and that it was experiencing enhanced delinquencies in its loan portfolio and had implemented various strategies to attempt to address this challenge. On May 13, 2020, Velocity announced its financial and operational results for the first quarter of 2020 the same quarter in which the IPO was conducted. The Company stated that its net income had decreased 50 sequentially during the quarter to just 2.6 million.By May 15, 2020, Velocity stock was trading at just 2.53 per share more than 80 below the 13.00 price investors paid for the stock in the IPO just four months previously.The complaint, filed on July 29, 2020, alleges that defendants failed to disclose that, at the time of the IPO, the Companys non-performing loans had dramatically increased in size from the figures provided in the offering materials, as measured by both the amount of unpaid principal balance and as a percentage of the Companys overall loan portfolio. In addition, defendants failed to provide any information to investors regarding the potential impact of the novel coronavirus on Velocitys business and operations, despite the fact that the international spread of the virus had already been confirmed at the time of the IPO. The failure to disclose the substantial and growing proportion of the Companys loans that were non-performing andor on non-accrual status as of the IPO rendered the statements contained in the Offering Materials regarding the quality of the Companys loan portfolio and underwriting practices materially misleading.For more information on the Velocity class action go to: Corp. NYSE: FEClass Period: February 21, 2017 to July 21, 2020Lead Plaintiff Deadline: September 28, 2020On July 21, 2020, federal agents announced the arrest of Ohio Speaker Larry Householder and four other persons, including a prominent FirstEnergy lobbyist, in connection with a 60 million racketeering and bribery scheme.On this news, the Companys share price fell by 7.01, or 17, to close at 34.25 per share on July 21, 2020.On July 22, 2020, Cleveland.com published an article entitled FirstEnergy was relentless in quest to have Ohio legislature bail out the utilitys nuclear plants, which provided further details regarding FirstEnergys illicit activities.On this news, the Companys share price fell by 7.16, or 21, to close at 27.09 per share on July 22, 2020.The complaint, filed on July 28, 2020, alleges that throughout the Class Period defendants made materially false andor misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: 1 that FirstEnergy and its representatives and affiliates had orchestrated a 60 million campaign to corrupt the political process in order to secure the passage of legislation favoring the Company and its affiliates; 2 that FirstEnergy and its representatives and affiliates had secretly funneled tens of millions of dollars to Ohio politicians to bribe those politicians in order to secure votes in favor of Ohio House Bill 6 HB6, a 1.3 billion ratepayer bailout for FirstEnergys unprofitable nuclear facilities; 3 that FirstEnergy and its representatives and affiliates had conducted a massive, misleading advertising campaign in support of HB6 and in opposition to a ballot initiative to repeal HB6 by passing millions of dollars through an intricate web of dark money entities and front companies in order to conceal the Companys involvement; 4 that FirstEnergy and its representatives and affiliates had subverted a citizens ballot initiative to repeal HB6 by, among other unscrupulous tactics, hiring more than 15 signature gathering firms and thus conflicting them out of supporting the initiative and bribing ballot initiative insiders and signature collectors; 5 that, as a result of the foregoing, defendants Class Period statements regarding FirstEnergys regulatory and legislative efforts were materially false and misleading; and 6 that, as a result of the foregoing, FirstEnergy was subject to an extreme, undisclosed risk of reputational, legal and financial harm.For more information on the FirstEnergy class action go to: Pharma, Inc. NASDAQ: MEIP Class Period: August 2, 2017 and July 1, 2020Lead Plaintiff Deadline: October 9, 2020MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. MEI Pharmas clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase HDAC inhibitor.MEI Pharma and Helsinn Healthcare SA, a Swiss pharmaceutical corporation Helsinn, with which MEI Pharma had an exclusive worldwide license, development, manufacturing and commercialization agreement for Pracinostat in acute myeloid leukemia AML, myelodysplastic syndrome, and other potential indications the Helsinn License Agreement, were evaluating Pracinostat in, among other studies, a pivotal Phase 3 global registration clinical trial for the treatment of adults with newly diagnosed AML who are unfit to receive intensive chemotherapy the Phase 3 Pracinostat Trial. The Phase 3 Pracinostat Trial, which was initiated in June 2017, was a randomized, double-blind, placebo-controlled study that would enroll worldwide approximately 500 adults with newly diagnosed AML who are unfit to receive intensive chemotherapy. Patients were randomized 1:1 to receive Pracinostat or placebo with azacitidine as background therapy. The primary endpoint of the trial was overall survival.On July 2, 2020, MEI Pharma issued a press release announcing that it was discontinuing the Phase 3 Pracinostat Trial. Specifically, the Company advised that an interim futility analysis of the Phase 3 Pracinostat Trial, undertaken by the studys Independent Data Monitoring Committee IDMC, has demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group, and that based on the outcome of the interim analysis, the decision was made to discontinue the recruitment of patients and end the study, which was based on a lack of efficacy and not on safety concerns.Following the announcement, the Companys stock price fell 0.78 per share, or 18.27, to close at 3.49 per share on July 2, 2020.The complaint, filed on August 10, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Companys business, operational and compliance policies. Specifically, defendants made false andor misleading statements andor failed to disclose that: i MEI Pharma had overstated Pracinostats potential efficacy as an AML treatment for the target population; ii consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; iii all the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Companys financial condition and prospects for Pracinostat; and iv as a result, the Companys public statements were materially false and misleading at all relevant times.For more information on the MEI Pharma class action go to: Oil Gas Corporation NYSE: COG Class Period: October 23, 2015 to June 12, 2020Lead Plaintiff Deadline: October 13, 2020Cabot was incorporated in 1989 and is headquartered in Houston, Texas. Cabot is an independent oil and gas company that explores for, exploits, develops, produces, and markets oil and gas properties in the U.S.Cabot primarily focuses its oil and gas efforts on the Marcellus Shale located in Susquehanna County, Pennsylvania. Cabots gas procuring activities in Pennsylvania have been the subject of controversy for over a decade, with the Company repeatedly denying any responsibility for environmental damage observed in the state.On July 26, 2019, Cabot filed a quarterly report on Form 10-Q with the SEC, reporting the Companys financial and operating results for the quarter ended June 30, 2019 the 2Q19 10-Q. The 2Q19 10-Q disclosed that the Company had received two proposed Consent Order and Agreements COAs related to two Notices of Violation NOVs it had received from the Pennsylvania Department of Environmental Protection PaDEP back in June and November, 2017, respectively, for failure to prevent the migration of gas into fresh groundwater sources in the area surrounding Susquehanna County, Pennsylvania.Following the release of the 2Q19 10-Q, Cabots stock price fell 2.63 per share, or 12.07, to close at 19. 